Manufacturer of Controlled Substances; Notice of Registration; Johnson Matthey, Inc., Pharmaceuticals Materials, 30028-30029 [2012-12244]
Download as PDF
<![CDATA[
30028
Federal Register / Vol. 77, No. 98 / Monday, May 21, 2012 / Notices
The company plans to manufacture the
listed controlled substances in bulk for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Siegfried (USA), to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Siegfried (USA), to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR
§ 1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: May 11, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
BILLING CODE 4410–09–P
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cedarburg Pharmaceuticals, Inc.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cambrex Charles City, Inc.
By Notice dated September 27, 2011,
and published in the Federal Register
on October 7, 2011, 76 FR 62449,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
ebenthall on DSK5SPTVN1PROD with NOTICES
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
II
II
II
The company plans to manufacture
the listed controlled substance
Noroxymorphone (9668), in bulk for
sale to its customers. It plans to
manufacture the other two listed
controlled substances in bulk for dosage
form development, clinical trials, and
use in stability qualification studies.
No comments or objections have been
received. DEA has considered the
Jkt 226001
By Notice dated January 6, 2012, and
published in the Federal Register on
January 17, 2012, 77 FR 2324, Cedarburg
Pharmaceuticals, Inc., 870 Badger
Circle, Grafton, Wisconsin 53024, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
4-Anilino-N-phenethyl-4-piperidine
(8333).
Fentanyl (9801) ............................
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Regarding the drug code (8333), the
company plans to use this controlled
substance to manufacture another
controlled substance.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cedarburg Pharmaceuticals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
investigated Cedarburg Pharmaceuticals,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: May 11, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12271 Filed 5–18–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Johnson Matthey, Inc.,
Pharmaceuticals Materials
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
18:18 May 18, 2012
Dated: May 11, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12275 Filed 5–18–12; 8:45 am]
[FR Doc. 2012–12274 Filed 5–18–12; 8:45 am]
VerDate Mar<15>2010
factors in 21 U.S.C. 823(a), and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
By Notice dated January 6, 2012, and
published in the Federal Register on
January 17, 2012, 77 FR 2324, Johnson
Matthey, Inc., Pharmaceuticals
Materials, 900 River Road,
Conshohocken, Pennsylvania 19428,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Schedule
I
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers. The Thebaine
(9333) will also be used to manufacture
other controlled substances in bulk
which will also be for sale in bulk to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc., Pharmaceuticals
Materials to manufacture the listed basic
E:\FR\FM\21MYN1.SGM
21MYN1
Federal Register / Vol. 77, No. 98 / Monday, May 21, 2012 / Notices
classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Johnson
Matthey Inc., Pharmaceuticals Materials
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: May 11, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12244 Filed 5–18–12; 8:45 am]
BILLING CODE 4410–09–P
NATIONAL SCIENCE FOUNDATION
Advisory Committee for International
Science and Engineering; Notice of
Meeting
ebenthall on DSK5SPTVN1PROD with NOTICES
In accordance with the Federal
Advisory Committee Act (Pub. L. 92–
463, as amended), the National Science
Foundation announces the following
meeting:
Name: Advisory Committee for
International Science and Engineering
(25104).
Date and Time: June 11, 2012, 10:00 a.m.–
12:00 p.m.
Place: Videoconference. The public is
welcome to attend at National Science
Foundation, 4201 Wilson Blvd., Room II–
1155, Arlington, VA. Videoconference
participation is only available for Committee
Members.
Type of Meeting: Open.
Contact Person for More Information:
Robert Webber, Office of International
Science and Engineering, National Science
Foundation, 4201 Wilson Blvd., Arlington,
VA, Telephone: 703–292–7569. If you wish
to attend the meeting and need access to the
NSF building, please contact the individual
listed above so your name may be added to
the building access list.
Purpose of Meeting: To provide advice and
recommendations concerning support for
research, education and related activities
involving the U.S. science and engineering
community working in a global context as
well as strategic efforts to promote a more
effective NSF role in international science
and engineering.
Agenda: Discuss strategies to identify
where STEM research and education will be
in 2020.
VerDate Mar<15>2010
18:18 May 18, 2012
Jkt 226001
Dated: May 16, 2012.
Susanne Bolton,
Committee Management Officer.
NUCLEAR REGULATORY
COMMISSION
[FR Doc. 2012–12189 Filed 5–18–12; 8:45 am]
BILLING CODE 7555–01–P
NUCLEAR REGULATORY
COMMISSION
[Docket No. 50–293–LR; ASLBP No. 12–
920–07–LR–BD01]
Entergy Nuclear Operations, Inc.;
Establishment of Atomic Safety and
Licensing Board
Pursuant to delegation by the
Commission dated December 29, 1972,
published in the Federal Register, 37 FR
28,710 (1972), and the Commission’s
regulations, see, e.g., 10 CFR 2.104,
2.300, 2.309, 2.313, 2.318, and 2.321,
notice is hereby given that an Atomic
Safety and Licensing Board (Board) is
being established to preside over the
following proceeding:
Entergy Nuclear Operations, Inc.
(Pilgrim Nuclear Power Station)
A Licensing Board is being
established to consider a petition filed
on May 2, 2012 by Jones River
Watershed Association and by Pilgrim
Watch seeking leave to reopen the
record and request a hearing. The
petition pertains to the January 25, 2006
application from Entergy Nuclear
Operations, Inc. to renew for an
additional twenty years the current
operating license for Pilgrim Nuclear
Power Station, which expires on June 8,
2012.
The Board is comprised of the
following administrative judges:
Ann Marshall Young, Chair, Atomic
Safety and Licensing Board Panel,
U.S. Nuclear Regulatory Commission,
Washington, DC 20555–0001.
Paul B. Abramson, Atomic Safety and
Licensing Board Panel, U.S. Nuclear
Regulatory Commission, Washington,
DC 20555–0001.
Richard F. Cole, Atomic Safety and
Licensing Board Panel, U.S. Nuclear
Regulatory Commission, Washington,
DC 20555–0001.
All correspondence, documents, and
other materials shall be filed in
accordance with the NRC E-filing rule,
which the NRC promulgated in August
2007 (72 FR 49,139).
Issued at Rockville, Maryland, this 15th
day of May 2012.
E. Roy Hawkens,
Chief Administrative Judge, Atomic Safety
and Licensing Board Panel.
[FR Doc. 2012–12213 Filed 5–18–12; 8:45 am]
BILLING CODE 7590–01–P
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
30029
Advisory Committee on Reactor
Safeguards; Notice of Meeting
In accordance with the purposes of
Sections 29 and 182b of the Atomic
Energy Act (42 U.S.C. 2039, 2232b), the
Advisory Committee on Reactor
Safeguards (ACRS) will hold a meeting
on June 6–8, 2012, 11545 Rockville
Pike, Rockville, Maryland.
Wednesday, June 6, 2012, Conference
Room T2–B1, 11545 Rockville Pike,
Rockville, Maryland
8:30 a.m.–8:35 a.m.: Opening
Remarks by the ACRS Chairman
(Open)—The ACRS Chairman will make
opening remarks regarding the conduct
of the meeting.
8:35 a.m.–10:00 a.m.: Proposed
Revision of 10 CFR Part 20 for
Conformance with International
Commission on Radiological Protection
(ICRP) Recommendations (Open)—The
Committee will hear presentations by
and hold discussions with
representatives of the NRC staff
regarding the proposed modifications to
10 CFR part 20 in order to conform to
current ICRP recommendations.
10:15 a.m.–11:45 a.m.: Disposition of
Near-Term Task Force (NTTF) Tier 3
Recommendations (Open)—The
Committee will hear presentations by
and hold discussions with
representatives of the NRC staff
regarding the staff’s plans for
implementation of the NTTF Tier 3
recommendations stemming from the
NRC’s evaluation of the Fukushima Daiichi accident.
12:45 p.m.–2:15 p.m.: Proposed
Revision 1 to Regulatory Guide (RG)
1.192, ‘‘Operation and Maintainability
Code Case Acceptability, ASME OM
Code’’ (Open)—The Committee will
hear presentations by and hold
discussions with representatives of the
NRC staff regarding the proposed
revision to RG 1.192, ‘‘Operation and
Maintainability Code Case
Acceptability, ASME OM Code.’’
2:30 p.m.–4:30 p.m.: Grand Gulf
Nuclear Station Unit 1 Extended Power
Uprate Application (Open/Closed)—The
Committee will hear presentations by
and hold discussions with
representatives of the NRC staff and
Entergy Operations Inc. regarding the
Grand Gulf Nuclear Station Unit 1
extended power uprate application.
[Note: A portion of this session may be
closed in order to discuss and protect
information designated as proprietary,
pursuant to 5 U.S.C. 552b(c)(4)].
E:\FR\FM\21MYN1.SGM
21MYN1
]]>Agencies
[Federal Register Volume 77, Number 98 (Monday, May 21, 2012)]
[Notices]
[Pages 30028-30029]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-12244]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration;
Johnson Matthey, Inc., Pharmaceuticals Materials
By Notice dated January 6, 2012, and published in the Federal
Register on January 17, 2012, 77 FR 2324, Johnson Matthey, Inc.,
Pharmaceuticals Materials, 900 River Road, Conshohocken, Pennsylvania
19428, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)........... I
Amphetamine (1100)......................... II
Methylphenidate (1724)..................... II
Codeine (9050)............................. II
Oxycodone (9143)........................... II
Hydrocodone (9193)......................... II
Morphine (9300)............................ II
Thebaine (9333)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for sale to its customers. The Thebaine (9333) will also be
used to manufacture other controlled substances in bulk which will also
be for sale in bulk to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Johnson Matthey Inc., Pharmaceuticals Materials to manufacture the
listed basic
[[Page 30029]]
classes of controlled substances is consistent with the public interest
at this time. DEA has investigated Johnson Matthey Inc.,
Pharmaceuticals Materials to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: May 11, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-12244 Filed 5-18-12; 8:45 am]
BILLING CODE 4410-09-P
